share_log

Recursion Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-RA Capital Management, L.P.(5.9%),Peter Kolchinsky(5.9%), etc.

Recursion Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-RA Capital Management, L.P.(5.9%),Peter Kolchinsky(5.9%), etc.

Recursion Pharmaceuticals | SC 13G：超過5%持股股東披露文件-RA Capital Management, L.P.(5.9%),Peter Kolchinsky(5.9%)等
美股sec公告 ·  07/08 16:22
Moomoo AI 已提取核心訊息
On June 28, 2024, RA Capital Management, L.P., along with Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., collectively known as the Reporting Persons, filed a Schedule 13G with the SEC, disclosing a 5.9% ownership stake in Recursion Pharmaceuticals, Inc. This stake amounts to 15,384,615 shares of Class A Common Stock. The filing indicates that RA Capital Management, L.P. serves as the investment adviser to the RA Capital Healthcare Fund, L.P., and may be deemed a beneficial owner of the securities held by the fund. The shares are reported based on the 260,812,291 shares of Class A Common Stock outstanding as of the closing of Recursion Pharmaceuticals' public offering. The Reporting Persons have disclaimed beneficial ownership of the reported securities except for the purpose of determining their obligations under Section 13(d) of the Act. The filing was completed on July 8, 2024, and includes a joint filing agreement among the Reporting Persons.
On June 28, 2024, RA Capital Management, L.P., along with Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., collectively known as the Reporting Persons, filed a Schedule 13G with the SEC, disclosing a 5.9% ownership stake in Recursion Pharmaceuticals, Inc. This stake amounts to 15,384,615 shares of Class A Common Stock. The filing indicates that RA Capital Management, L.P. serves as the investment adviser to the RA Capital Healthcare Fund, L.P., and may be deemed a beneficial owner of the securities held by the fund. The shares are reported based on the 260,812,291 shares of Class A Common Stock outstanding as of the closing of Recursion Pharmaceuticals' public offering. The Reporting Persons have disclaimed beneficial ownership of the reported securities except for the purpose of determining their obligations under Section 13(d) of the Act. The filing was completed on July 8, 2024, and includes a joint filing agreement among the Reporting Persons.
2024年6月28日，RA Capital Management、Peter Kolchinsky、Rajeev Shah和RA Capital Healthcare Fund合夥人共同向SEC提交了13G表格，披露其持有Recursion Pharmaceuticals公司的5.9%所有權，即15384615股A類普通股。文件顯示，RA Capital Management是RA Capital Healthcare Fund的投資顧問，並可能被視爲基金持有的證券的受益所有者。這些股份是根據Recursion Pharmaceuticals公開發行的260812291股A類普通股的收盤價報告的。除了確定其根據《證券交易法》第13(d)條款的義務外，通報人否認對所報告的證券享有有益所有權。該備案於2024年7月8日完成，幷包括通報人之間的聯合備案協議。
2024年6月28日，RA Capital Management、Peter Kolchinsky、Rajeev Shah和RA Capital Healthcare Fund合夥人共同向SEC提交了13G表格，披露其持有Recursion Pharmaceuticals公司的5.9%所有權，即15384615股A類普通股。文件顯示，RA Capital Management是RA Capital Healthcare Fund的投資顧問，並可能被視爲基金持有的證券的受益所有者。這些股份是根據Recursion Pharmaceuticals公開發行的260812291股A類普通股的收盤價報告的。除了確定其根據《證券交易法》第13(d)條款的義務外，通報人否認對所報告的證券享有有益所有權。該備案於2024年7月8日完成，幷包括通報人之間的聯合備案協議。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息